Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$99.39
+0.4%		$110.64
$63.23
▼
$130.00
$6.45B0.52891,014 shs112,029 shs
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
$54.80
+1.8%		$50.48
$27.07
▼
$58.49
$6.68B0.691.33 million shs217,323 shs
TRAX
First Tracks Biotherapeutics
$43.81
-5.0%		$29.33
$14.72
▼
$49.91
$1.52BN/A634,655 shs228,191 shs
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$64.12
-1.7%		$60.91
$35.60
▼
$72.66
$6.19B0.621.29 million shs150,636 shs
10 Best Stocks to Own - Summer 2026 Cover
10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
+0.75%-6.45%-16.86%-11.15%+52.92%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
+3.36%+12.20%-1.61%+4.95%+67.14%
TRAX
First Tracks Biotherapeutics
-1.33%-1.75%+31.76%+154.02%+4,612,999,900.00%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
+3.23%+1.49%-3.63%+16.54%+81.33%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$99.39
+0.4%		$110.64
$63.23
▼
$130.00
$6.45B0.52891,014 shs112,029 shs
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
$54.80
+1.8%		$50.48
$27.07
▼
$58.49
$6.68B0.691.33 million shs217,323 shs
TRAX
First Tracks Biotherapeutics
$43.81
-5.0%		$29.33
$14.72
▼
$49.91
$1.52BN/A634,655 shs228,191 shs
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$64.12
-1.7%		$60.91
$35.60
▼
$72.66
$6.19B0.621.29 million shs150,636 shs
10 Best Stocks to Own - Summer 2026 Cover
10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
+0.75%-6.45%-16.86%-11.15%+52.92%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
+3.36%+12.20%-1.61%+4.95%+67.14%
TRAX
First Tracks Biotherapeutics
-1.33%-1.75%+31.76%+154.02%+4,612,999,900.00%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
+3.23%+1.49%-3.63%+16.54%+81.33%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
2.93
Moderate Buy$137.3338.17% Upside
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
3.12
Buy$57.715.32% Upside
TRAX
First Tracks Biotherapeutics
2.89
Moderate Buy$60.5038.10% Upside
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
3.00
Buy$77.1320.30% Upside

Current Analyst Ratings Breakdown

Latest TRAX, SRRK, XENE, and MIRM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/13/2026
TRAX
First Tracks Biotherapeutics
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$54.00 ➝ $95.00
8/13/2026
TRAX
First Tracks Biotherapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$44.00 ➝ $57.00
8/13/2026
TRAX
First Tracks Biotherapeutics
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$48.00 ➝ $65.00
8/13/2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$56.00 ➝ $63.00
8/13/2026
TRAX
First Tracks Biotherapeutics
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$60.00 ➝ $70.00
8/10/2026
TRAX
First Tracks Biotherapeutics
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$45.00 ➝ $65.00
8/10/2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$65.00
8/10/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$74.00
8/10/2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$58.00
8/7/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$82.00 ➝ $81.00
8/7/2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$76.00
(Data available from 8/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$521.31M12.38$0.05 per share1,926.87($0.16) per share-621.20
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
N/AN/AN/AN/A$2.41 per shareN/A
TRAX
First Tracks Biotherapeutics
N/AN/AN/AN/AN/AN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$7.50M826.46N/AN/A$12.85 per share4.99
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
-$23.36M-$14.55N/AN/AN/A-139.18%-36.28%-8.54%N/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$377.94M-$3.45N/AN/AN/AN/A-159.92%-90.71%N/A
TRAX
First Tracks Biotherapeutics
N/A-$1.84N/AN/AN/AN/AN/AN/AN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$345.91M-$4.74N/AN/AN/AN/A-43.98%-41.72%N/A

Latest TRAX, SRRK, XENE, and MIRM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
TRAX
First Tracks Biotherapeutics
-$0.74-$0.95-$0.21-$0.95N/AN/A
8/6/2026Q2 2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$0.8405-$0.84+$0.0005-$0.84$3.33 millionN/A
8/6/2026Q2 2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$1.16-$1.11+$0.05-$1.11$1.67 millionN/A
8/5/2026Q2 2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
-$0.7425-$1.06-$0.3175-$1.06$166.33 million$176.24 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
N/AN/AN/AN/AN/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
N/AN/AN/AN/AN/A
TRAX
First Tracks Biotherapeutics
N/AN/AN/AN/AN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
1.28
2.86
2.74
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
0.71
8.64
8.64
TRAX
First Tracks Biotherapeutics
N/A
8.74
8.74
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/A
21.01
21.02

Institutional Ownership

CompanyInstitutional Ownership
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
N/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
91.08%
TRAX
First Tracks Biotherapeutics
N/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
95.45%

Insider Ownership

CompanyInsider Ownership
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
8.32%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
10.30%
TRAX
First Tracks Biotherapeutics
N/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
2.91%
CompanyEmployeesShares OutstandingFree FloatOptionable
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
14064.93 million59.53 millionOptionable
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
140121.79 million109.24 millionOptionable
TRAX
First Tracks Biotherapeutics
N/A34.89 millionN/AN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
21096.67 million93.85 millionOptionable

Recent News About These Companies

Q3 EPS Forecast for Xenon Pharmaceuticals Boosted by Analyst
August 13 at 1:28 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30957249
Xenon Pharmaceuticals: Strong Buy On Azetukalner NDA And MDD Expansion Opportunity
August 11 at 9:58 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4934652-xenon-pharmaceuticals-strong-buy-on-azetukalner-nda-and-mdd-expansion-opportunity
HC Wainwright Issues Positive Outlook for XENE Earnings
August 11 at 7:41 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-issues-positive-outlook-for-xene-earnings-2026-08-11/
Equities Analysts Set Expectations for XENE Q1 Earnings
August 10 at 1:43 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30951472
Brokers Issue Forecasts for XENE Q1 Earnings
August 10 at 1:41 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/brokers-issue-forecasts-for-xene-q1-earnings-2026-08-10/
Quantinno Capital Management LP Purchases 30,816 Shares of Xenon Pharmaceuticals Inc. $XENE
August 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-quantinno-capital-management-lp-purchases-30816-shares-of-xenon-pharmaceuticals-inc-xene-2026-08-09/
Xenon anticipates AZK NDA submission later this quarter, while funding operations into 2029
August 7, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4628882-xenon-anticipates-azk-nda-submission-later-this-quarter-while-funding-operations-into-2029
Xenon Pharmaceuticals' Azetukalner NDA Filing Remains on Track After FDA Meeting, RBC Says
August 7, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/xenon-pharmaceuticals-apos-azetukalner-nda-180212752.html
Xenon Pharmaceuticals Q2 Earnings Call Highlights
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/xenon-pharmaceuticals-q2-earnings-call-highlights-2026-08-07/
XENE's Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in Focus
August 7, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2971054/xene-s-q2-loss-narrower-than-expected-sales-nil-pipeline-in-focus?cid=cs-stocknewsapi-ft-analyst_blog|earnings_article-2971054
California State Teachers Retirement System Buys 36,183 Shares of Xenon Pharmaceuticals Inc. $XENE
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-california-state-teachers-retirement-system-buys-36183-shares-of-xenon-pharmaceuticals-inc-xene-2026-08-07/
Xenon Pharmaceuticals Inc. (XENE) Q2 2026 Earnings Call Transcript
August 7, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4932743-xenon-pharmaceuticals-inc-xene-q2-2026-earnings-call-transcript
Xenon Pharmaceuticals Q2 Loss Widens
August 7, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/xenon-pharmaceuticals-q2-loss-widens-213531400.html
Xenon Pharmaceuticals (NASDAQ:XENE) Announces Quarterly Earnings Results
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/xenon-pharmaceuticals-nasdaqxene-announces-quarterly-earnings-results-2026-08-06/
Xenon Reports Q2 2026 Financial Results and Provides Business Update
August 6, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/xenon-reports-q2-2026-financial-results-and-provides-business-update-1036422683
Xenon Pharma Q2 2026 earnings preview
August 6, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/xenon-pharma-q2-2026-earnings-preview/ar-AA29u2E5
Xenon Pharmaceuticals Inc. $XENE Shares Bought by Sei Investments Co.
August 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-xenon-pharmaceuticals-inc-xene-shares-bought-by-sei-investments-co-2026-08-04/
Xenon Pharmaceuticals (XENE) to Release Earnings on Thursday
August 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/xenon-pharmaceuticals-xene-to-release-earnings-on-thursday-2026-08-02/
Lazard Asset Management LLC Sells 27,908 Shares of Xenon Pharmaceuticals Inc. $XENE
August 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-lazard-asset-management-llc-sells-27908-shares-of-xenon-pharmaceuticals-inc-xene-2026-08-02/
Xenon Pharmaceuticals (NASDAQ:XENE) Raised to Sell at Wall Street Zen
August 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/xenon-pharmaceuticals-nasdaqxene-raised-to-sell-at-wall-street-zen-2026-08-01/
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 31, 2026  |  financialpost.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

Mirum Pharmaceuticals stock logo

Mirum Pharmaceuticals NASDAQ:MIRM

$99.39 +0.42 (+0.43%)
As of 12:23 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Scholar Rock stock logo

Scholar Rock NASDAQ:SRRK

$54.80 +0.98 (+1.82%)
As of 12:22 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

First Tracks Biotherapeutics NASDAQ:TRAX

$43.81 -2.32 (-5.03%)
As of 12:23 PM Eastern
This is a fair market value price provided by Massive. Learn more.

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.

Xenon Pharmaceuticals stock logo

Xenon Pharmaceuticals NASDAQ:XENE

$64.12 -1.14 (-1.75%)
As of 12:23 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas